-
Journal of Experimental Pharmacology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose–insulin homeostasis in animal models
Original Research
(6369) Views (864) Full article downloads
Authors: S K Mastan, K Eswar Kumar
Published Date December 2009
Volume 2010:2 Pages 1 - 11
DOI: http://dx.doi.org/10.2147/JEP.S8129
S K Mastan1, K Eswar Kumar2
1Research and Development Cell, Jawaharlal Nehru Technological University, Hyderabad, Andhra Pradesh, India; 2Pharmacology Division, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India
Abstract: The objective of this study was to investigate the effect of oral administration of antiretroviral drugs (indinavir, ritonavir, atazanavir, efavirenz and nevirapine) on the pharmacodynamics of gliclazide in rats (normal and diabetic) and rabbits with respect to glucose–insulin homeostasis to evaluate the safety and effectiveness of the combinations. Blood samples were collected at regular time intervals in rats from retro orbital puncture and by marginal ear vein puncture in rabbits. All the blood samples were analyzed for blood glucose by glucose oxidase–peroxidase method and insulin by a radio immuno assay method. The insulin resistance index and β-cell function were determined by a homeostasis model assessment. Indinavir and ritonavir alone had significant impact on glucose–insulin homeostasis in animal models among the antiretroviral drugs used in our study. In combination, indinavir and efavirenz significantly reduced the activity of gliclazide, while ritonavir and atazanavir significantly increased the activity of gliclazide. However, nevirapine had no significant effect on the activity of gliclazide. From this study we conclude that glucose–insulin homeostasis disorders associated with antiretroviral drugs are not class-specific, but are drug-specific. So care should be taken when indinavir, ritonavir, atazanavir and efavirenz are prescribed for diabetic patients.
Keywords: protease inhibitors, efavirenz, nevirapine, gliclazide, homeostasis model assessment, diabetes
Other articles by Mr SK Mastan
The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/BE) studies – an overview
Readers of this article also read:
Potential renovascular hypertension, space missions, and the role of magnesium
Potential antidiabetic and antioxidant activities of Morus indica and Asystasia gangetica in alloxan-induced diabetes mellitus
Cystone - An ayurvedic polyherbal formulation inhibits adherence of uropathogenic E coli and modulates H2O2 induced toxicity in NRK 52E cells
Cardioprotective and β-adrenoceptor antagonistic activity of a newly synthesized aryloxypropanolamine derivative PP-36
Effects of an oral dose of l-glutamic acid on circulating neurotransmitters: Possible roles of the C1(Ad) and the A5(NA) pontomedullary nuclei
Effect of amlodipine, a calcium channel antagonist, on gonadal steroid of male wistar albino rats
Nephroprotection of lacidipine against gentamycin-induced nephrotoxicity in albino rats
The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/BE) studies – an overview
Drug-resistant tuberculosis: emerging treatment options
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




